Search

Displaying results 9521 - 9530 of 10000 in total
  1. Drug

    AB192

    go.drugbank.com/drugs/DB06111
    Experimental

    AB192 is a DPP IV enzymatic activity inhibitor.

  2. Drug

    GW-559090

    go.drugbank.com/drugs/DB06508
    Experimental

  3. Drug

    Edaglitazone

    go.drugbank.com/drugs/DB06519
    Investigational

  4. Drug

    Tramiprosate

    go.drugbank.com/drugs/DB06527
    Investigational

  5. Drug

    Dextofisopam

    go.drugbank.com/drugs/DB06582
    Investigational

  6. Drug

    Omiganan

    go.drugbank.com/drugs/DB06610
    Investigational

    Omiganan has been investigated for the treatment of Mupirocin-resistant MRSA skin infections.

  7. Drug

    Onametostat

    go.drugbank.com/drugs/DB21480
    Investigational

    The usage of the INN stem '-metostat' in the name indicates that Onametostat is a histone N-methyltransferase inhibitor. … Onametostat is under investigation in clinical trial NCT06788509 (A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring).

  8. Drug

    Nifurethazone

    go.drugbank.com/drugs/DB20112
    Experimental

    The usage of the INN stem '-azone' in the name indicates that Nifurethazone is a anti-inflammatory analgesic, phenylbutazone derivative. … The usage of the INN stem 'nifur-' in the name indicates that Nifurethazone is a 5-nitrofuran derivative. Nifurethazone has a monoisotopic molecular weight of 269.11 Da.

  9. Drug

    Nifurizone

    go.drugbank.com/drugs/DB19694
    Experimental

    The usage of the INN stem '-zone' in the name indicates that Nifurizone is a anti-inflammatory analgesic, phenylbutazone derivative. … The usage of the INN stem 'nifur-' in the name indicates that Nifurizone is a 5-nitrofuran derivative. Nifurizone has a monoisotopic molecular weight of 307.09 Da.

  10. Drug

    FINLAY-FR-1

    go.drugbank.com/drugs/DB16524
    Experimental

    , of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. … It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity